The CSL Limited (ASX: CSL) share price is having another off day on Friday despite the release of a potentially positive announcement.

In afternoon trade the biotherapeutics company’s shares are down 3% to $285.04. This means the CSL share price is now down 17% from its 52-week high.

What did CSL announce?

This morning CSL revealed that it has entered into a new, significant partnering agreement to accelerate the development, manufacture, and distribution of a COVID-19 vaccine candidate.

The agreement has been made with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Queensland. It formalises the support provided by the company to the two parties since the onset of the pandemic earlier this year.

CEPI and CSL will fund the development and manufacture of the University of Queensland’s “molecular clamp” enabled vaccine. This is a transformative technology patented by the university’s technology transfer company.  It enables rapid vaccine design and production against outbreak viral pathogens.

According to the release, the university is aiming to take the vaccine candidate into a phase 1 clinical trial in July. Should its clinical trials be successful, a vaccine could be available for distribution in 2021.

While acknowledging that there is still a lot of work to be done, CSL believes its production technology can be scaled to produce up to one hundred million doses towards the end of 2021.

It would also subcontract other global manufacturers. This would increase the number of doses that can be produced and broaden the geographical distribution of vaccine production.

That is of course if other companies such as Moderna don’t get there first with the vaccines they have in clinical trials at present.

A “promising vaccine.”

Professor Andrew Cuthbertson, CSL’s Chief Scientific Officer, commented: “We are very pleased to be able to provide our scientific expertise and platform technologies to make a strong contribution to this critical joint effort with CEPI, the University of Queensland and others.”

“CSL will contribute to UQ’s promising vaccine with our proprietary adjuvant, MF59, made by Seqirus, along with expertise in process science and scale-up from our Australian facilities, managing advanced clinical trials and the large-scale manufacture of the recombinant vaccine,” he added.

The Chief Scientific Officer concluded: “Should trials be successful, this vaccine holds the potential to provide protection against this urgent public health emergency for Australians and those around the world vulnerable to this devastating virus.”

More reading

• Brokers name 3 ASX shares to buy today
• 2 ASX growth shares I’d buy before Afterpay shares
• Why Appen, CSL, Openpay, & Zip Co shares are tumbling lower
• The 10 shares that significantly move the ASX 200 index
• 3 top ETFs you can easily diversify your portfolio with immediately

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post CSL share price lower despite COVID-19 vaccine news appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2A4JMBF

The Aumake International Ltd (ASX: AU8) share price is zooming higher today after the company announced it now offers leading Chinese-owned buy now, pay later (BNPL) services via its in-store and online channels.

AuMake is a specialist retailer that caters for Asian tourists and daigou personal shoppers in Australia and New Zealand. The company has a multichannel distribution network, selling Australian and New Zealand products online via owned and third-party channels, and through brick and mortar stores.

The company operates 15 stores under the AuMake and Broadway brands, located along the east coast of Australia and in New Zealand. These stores primarily cater to organised tour groups. The types of products on offer include skincare, health supplements, wool, honey and clothing.

Before we dig into the announcement, it’s important to note that AuMake sits at the very small end of the ASX with a current market capitalisation of around $21 million. At the time of writing, the AuMake share price is sitting 10.34% higher for the day at 6.4 cents after rallying as much as 27.59% in early morning trade.

What did AuMake announce?

This morning, AuMake revealed that it now supports BNPL services for its in-store customers and 40,000-strong online database.

Accordingly, AuMake’s customers will be able to use Alipay’s “Huabei” feature and Tencent’s “Fenfu” feature to make purchases.

Alipay is one of the most popular online payment solutions in China and falls under the umbrella of Chinese multinational giant Alibaba.

Huabei allows purchases made via the Alipay wallet to be paid using credit facilitates, including interest-free or daily incurring interest loans. According to AuMake’s announcement, Huabei has more than 190 million users, with 93% of them being under the age of 35.

Meanwhile, rival conglomerate Tencent is reportedly in the final stages of developing its Fenfu BNPL credit feature. Fenfu will offer similar credit facilities to Huabei that can be used by its 1.1 billion customer base.

Tencent recently made headlines in the ASX BNPL space after news broke that it had acquired a 5% stake in market darling Afterpay Ltd (ASX: APT).

AuMake believes the adoption of these BNPL payment methods will assist the company to penetrate a younger Asian customer demographic. The retailer concluded today’s announcement by stating it will continue to assess initiatives that provide a contemporary shopping experience for its customers.

According to Market Index, the 4-week average turnover of AuMake shares currently sits at only $26,821. So if you’d rather invest in larger and more liquid companies, the top ASX shares in the free report below might be more up your alley.

More reading

• Here’s why CBA shares are a good buy today
• 3 more founder-led ASX 200 shares to buy today
• 3 tips for surviving an ASX recession
• CSL share price lower despite COVID-19 vaccine news
• Why Alumina and Stockland share prices could outperform in coming weeks

Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the AuMake share price surged 28% higher today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3dzHoBH

The Alumina Limited (ASX: AWC) share price and Stockland Corporation Ltd (ASX: SGP) share price are likely to outperform even as doubts emerge on the short-term direction for the S&P/ASX 200 Index (Index:^AXJO).

The bullish take on both stocks come from Morgan Stanley, which is predicting that their share prices will rise in absolute terms over the next 60 days.

If the broker’s prediction is right, it would be a welcomed relief for shareholders as the aluminium producer and property group have underperformed since the COVID-19 outbreak.

The disruption to the global economy has weighed on the price of alumina, while pressure on residential and retail properties have put real estate stocks in the sin bin.

But this may be about to change.

Set for a rebound

“The alumina price is bouncing off support levels, with AWC offering a clean exposure (CY20e 5% aluminium revenue exposure),” said the broker.

“We expect unprofitable alumina producers to exit the market, given the ease of shutting and restarting refineries.

“We think 2020 will provide the low-point for alumina input costs, and cost inflation could help to buoy prices.”

Dividend looks safe

While no one believes the price of the commodity is set to surge, Morgan Stanley believes it will hover somewhere below the marginal cost of production of Chinese smelters, which is estimated at around US$285 a tonne.

At that price, Alumina is well placed to generate a decent dividend for investors at around 4.5% in calendar 2020 and 3.4% the following year.

It’s not a big dividend but it’s enough to compensate investors to hang on to the stock in anticipation of the alumina price recovery.

Morgan Stanley estimates there is a 70% to 80% chance that the Alumina share price will rise in the next two months. The broker’s recommendation on the stock is “overweight” (or “buy”) with a $2.05 a share price target.

HomeBuilder stimulates Stockland

Meanwhile, Morgan Stanley is tipping a 60% to 70% chance that the Stockland share price will trend in the same direction over a similar period.

This is thanks to the recently announced $688 million HomeBuilder grant from the federal government.

The grant gives eligible new home buyers a $25,000 handout for properties that are worth under $750,000.

Well placed to benefit

“This is in SGP’s sweet-spot,given 70-80% of its products are sold to owner-occupiers/First Home Buyers,and its properties are at the affordable end (eg Sydney house & land entry price c.A$720k),” said Morgan Stanley.

“This will be a material positive for SGP’s FY21 outlook as we transition out of COVID-19.”

The broker recently upgraded Stockland to “overweight” with a price target of $4.30 a share.

More reading

• 2 ASX REITs to buy with $1,000 today
• We’re in recession. What does that mean for investors?
• ASX 200 down 0.35%: UBS upgrades NAB and Westpac, Qantas soars again
• 3 of the best ASX 200 tech shares for your watchlist
• The Kogan share price is surging higher following another positive business update

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Alumina and Stockland share prices could outperform in coming weeks appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/371qeu8